| Priorities for the US health community responding to COVID-19 AA Adalja, E Toner, TV Inglesby Jama 323 (14), 1343-1344, 2020 | 372 | 2020 |
| Lessons learned during dengue outbreaks in the United States, 2001–2011 AA Adalja, TK Sell, N Bouri, C Franco Emerging infectious diseases 18 (4), 608, 2012 | 154 | 2012 |
| A novel international monkeypox outbreak A Adalja, T Inglesby Annals of internal medicine 175 (8), 1175-1176, 2022 | 135 | 2022 |
| Antimicrobial resistance is a global health emergency E Toner, A Adalja, GK Gronvall, A Cicero, TV Inglesby Health security 13 (3), 153-155, 2015 | 131 | 2015 |
| Absorbing citywide patient surge during Hurricane Sandy: a case study in accommodating multiple hospital evacuations AA Adalja, M Watson, N Bouri, K Minton, RC Morhard, ES Toner Annals of emergency medicine 64 (1), 66-73. e1, 2014 | 103 | 2014 |
| Broad-spectrum antiviral agents: a crucial pandemic tool A Adalja, T Inglesby Expert review of Anti-infective Therapy 17 (7), 467-470, 2019 | 95 | 2019 |
| Return of epidemic dengue in the United States: implications for the public health practitioner N Bouri, TK Sell, C Franco, AA Adalja, DA Henderson, NA Hynes Public Health Reports 127 (3), 259-266, 2012 | 94 | 2012 |
| Clinical management of potential bioterrorism-related conditions AA Adalja, E Toner, TV Inglesby New England Journal of Medicine 372 (10), 954-962, 2015 | 83 | 2015 |
| Global catastrophic biological risks: toward a working definition M Schoch-Spana, A Cicero, A Adalja, G Gronvall, T Kirk Sell, D Meyer, ... Health security 15 (4), 323-328, 2017 | 82 | 2017 |
| Antibiotic consumption and stewardship at a hospital outside of an early coronavirus disease 2019 epicenter DJ Buehrle, BK Decker, MM Wagener, A Adalja, N Singh, MC McEllistrem, ... Antimicrobial agents and chemotherapy 64 (11), 10.1128/aac. 01011-20, 2020 | 57 | 2020 |
| An estimate of the global health care and lost productivity costs of dengue FW Selck, AA Adalja, CR Boddie Vector-Borne and Zoonotic Diseases 14 (11), 824-826, 2014 | 57 | 2014 |
| Characteristics of microbes most likely to cause pandemics and global catastrophes AA Adalja, M Watson, ES Toner, A Cicero, TV Inglesby Global catastrophic biological risks, 1-20, 2019 | 50 | 2019 |
| Challenges and opportunities of nontraditional approaches to treating bacterial infections BN Tse, AA Adalja, C Houchens, J Larsen, TV Inglesby, R Hatchett Clinical Infectious Diseases 65 (3), 495-500, 2017 | 46 | 2017 |
| Original antigenic sin and pandemic (H1N1) 2009 AA Adalja, DA Henderson Emerging infectious diseases 16 (6), 1028, 2010 | 46 | 2010 |
| Genetically modified (GM) mosquito use to reduce mosquito-transmitted disease in the US: a community opinion survey A Adalja, TK Sell, M McGinty, C Boddie PLoS currents 8, 2016 | 40 | 2016 |
| Enabling emergency mass vaccination: innovations in manufacturing and administration during a pandemic D Hosangadi, KL Warmbrod, EK Martin, A Adalja, A Cicero, T Inglesby, ... Vaccine 38 (26), 4167-4169, 2020 | 34 | 2020 |
| Isolation of Aspergillus in three 2009 H1N1 influenza patients AA Adalja, PL Sappington, SP Harris, T Rimmele, JW Kreit, JA Kellum, ... Influenza and Other Respiratory Viruses 5 (4), 225-229, 2011 | 33 | 2011 |
| Preparedness for a high-impact respiratory pathogen pandemic JB Nuzzo, L Mullen, M Snyder, A Cicero, TV Inglesby, AA Adalja, ... Baltimore, MD, USA: Johns Hopkins Center for Health Security, 2019 | 32 | 2019 |
| The characteristics of pandemic pathogens AA Adalja, M Watson, ES Toner, A Cicero, TV Inglesby Johns Hopkins Center for Health Security: Baltimore, MD, USA, 28, 2018 | 32 | 2018 |
| Assessment of serosurveys for H5N1 ES Toner, AA Adalja, JB Nuzzo, TV Inglesby, DA Henderson, DS Burke Clinical infectious diseases 56 (9), 1206-1212, 2013 | 29 | 2013 |
